ZIOPHARM Oncology, Inc. (ZIOP) EPS Estimated At $-0.12

October 13, 2018 - By Louis Casey

Analysts expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to report $-0.12 EPS on November, 5.They anticipate $0.01 EPS change or 7.69 % from last quarter’s $-0.13 EPS. After having $-0.12 EPS previously, ZIOPHARM Oncology, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 4.14% or $0.11 during the last trading session, reaching $2.55. About 1.88 million shares traded or 55.40% up from the average. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has declined 54.20% since October 13, 2017 and is downtrending. It has underperformed by 69.82% the S&P500.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

Among 2 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 1 have Buy rating, 1 Sell and 0 Hold. Therefore 50% are positive. Ziopharm Oncology had 2 analyst reports since May 14, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Monday, May 14 by H.C. Wainwright. The stock has “Underweight” rating by JP Morgan on Monday, June 18.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company has market cap of $360.01 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon??s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma . It currently has negative earnings. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

More news for ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) were recently published by: Benzinga.com, which released: “26 Stocks Moving In Tuesday’s Pre-Market Session” on October 09, 2018. Globenewswire.com‘s article titled: “Ziopharm and Precigen Redefine Relationships, Announce New License Agreement” and published on October 09, 2018 is yet another important article.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News